Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.
In the rapidly advancing field of molecular medicine, researchers are constantly on the lookout for innovative therapies that can target specific disease molecules with precision and efficacy. Aptamers, a class of synthetic oligonucleotides, have emerged as a promising and versatile tool in the quest for… Read More »Aptamers: A Novel Therapeutic Oligonucleotide
Aptamers are engineered molecules that can bind to specific target compounds with high affinity and selectivity, making them valuable tools in various applications. Achieving absolute specificity, or binding to a single compound exclusively, is challenging due to the structural similarities among molecules. However, aptamers can… Read More »The Specificity of Aptamers: Can They Selectively Bind to a Single Compound?
Cancer is a formidable adversary that continues to challenge the field of medicine. Despite significant advancements in cancer research and treatment, finding precise and effective methods for diagnosing and treating cancer remains a top priority. One promising avenue of research that has gained momentum in… Read More »Targeted Hope: Aptamers in the Fight Against Cancer
Aptamers are synthetic, single-stranded DNA, RNA, or peptide molecules with high specificity and affinity for a wide range of target molecules, making them valuable in diagnostics. Advantages of aptamers in diagnostics include high specificity, versatility for various target types, and stability under different environmental conditions.… Read More »Aptamers: Revolutionizing Diagnostics in the Next Generation
In the realm of modern medicine, researchers and scientists are continually exploring innovative ways to combat diseases and improve the quality of life for patients. Two emerging contenders in the therapeutic arena are antibodies and aptamers. These molecular warriors hold immense potential in diagnosing and… Read More »A Therapeutic Battle: Antibodies vs. Aptamers
One of the most remarkable aspects of the integration of aptamers with qPCR for protein detection is the unprecedented sensitivity it brings to the table. Traditional protein detection methods, such as ELISA and Western blotting, often struggle to accurately quantify proteins present in very low… Read More »Advancements in Sensitivity: qPCR’s Remarkable Detection of Proteins
We are pleased to announce that our European subsidiary company, NeoNeuro has recently succeeded with a pre-clinical trial of their blood test for brain amyloid with the collaboration of the Centro Hospitalar de Entre o Douro e Vouga, in Santa Maria da Fiera, Portugal. This… Read More »Successful Pre-clinical Trial of Aptamer-based Blood Test for Alzheimer’s Disease
Welcome to the forefront of scientific exploration, where the power of aptamers is reshaping the boundaries of medicine, diagnostics, and beyond. The aptamer frontier represents a captivating realm of discovery, where researchers and innovators are unlocking previously unimaginable applications and uncharted possibilities. In this blog,… Read More »The Aptamer Frontier: Discovering New Applications and Possibilities
Aptamers, versatile nucleic acid molecules with tremendous potential for targeted therapies and diagnostics, have gained significant attention in recent years. We are among the key players in this exciting field, known for our leadership in aptamer patenting. With employees named on 85 published patent applications… Read More »Innovating the Landscape of Aptamer Intellectual Property: A Look Inside NeoVentures and NeoNeuro
In recent years, the field of therapeutics has witnessed remarkable advancements in the development of novel treatment strategies. Among the emerging approaches, aptamers have emerged as powerful tools with immense potential in various therapeutic applications. Aptamers, short single-stranded nucleic acid or peptide molecules, can specifically… Read More »Unlocking Therapeutic Potential: Aptamers as Promising Tools in Medicine
